Canasa Suppository
NDC Package 58914-501-33

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Canasa (mesalamine) suppositories is mesalamine (also known as 5-aminosalicylic acid) is used to treat ulcerative proctitis, a type of bowel disease. This formulation utilizes a suppository delivery system. Marketed by Allergan, Inc., this product is identified by NDC 58914-501 and is authorized under FDA application NDA021252.

Identification & Billing

NDC Package Code
58914-501-33
Package Description
3 SUPPOSITORY in 1 BOX
Product Code
58914-501
11-Digit Billing Format
58914050133
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Canasa
Non-Proprietary Name
Mesalamine
Substance Name
Mesalamine
Dosage Form
Suppository - A solid body of various weights and shapes, adapted for introduction into the rectal orifice of the human body; they usually melt, soften, or dissolve at body temperature.
Administration Route
Rectal - Administration to the rectum.
Active Ingredient(s)
MESALAMINE 1000 mg/1
Pharmacologic Class
Usage Information
Mesalamine (also known as 5-aminosalicylic acid) is used to treat ulcerative proctitis, a type of bowel disease. It does not cure ulcerative proctitis, but it may decrease the number of stools, the amount of mucus/blood in the stools, and the rectal bleeding caused by irritation/swelling of the colon/rectum. Mesalamine is an aminosalicylate anti-inflammatory drug. It is believed to work by blocking the production of certain natural chemicals that may cause pain and swelling.

Regulatory & Marketing

Labeler Name
Allergan, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA021252
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-05-2001
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (58914-501). Click a package code to view its specific billing and regulatory data.

58914-501-42
42 SUPPOSITORY in 1 BOX
58914-501-56
30 SUPPOSITORY in 1 BOX

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58914-501-33 identifies a specific commercial package of 3 suppository in 1 box of Canasa, a human prescription drug labeled by Allergan, Inc.. This suppository is formulated for rectal use and contains mesalamine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allergan, Inc. on January 05, 2001. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Mesalamine (also known as 5-aminosalicylic acid) is used to treat ulcerative proctitis, a type of bowel disease. It does not cure ulcerative proctitis, but it may decrease the number of stools, the amount of mucus/blood in the stools, and the rectal bleeding caused by irritation/swelling of the colon/rectum. Mesalamine is an aminosalicylate anti-inflammatory drug. It is believed to work by blocking the production of certain natural chemicals that may cause pain and swelling.

How is this Allergan, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58914050133. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
58914-501-33
11-Digit CMS (5-4-2)
58914-0501-33

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.